sur SARTORIUS STED BIO (EPA:DIM)
Sartorius Stedim Biotech SA: Provision of financial documents
Sartorius Stedim Biotech Group has announced the availability of financial results for the first half of 2024. Investors can access detailed information via the following link:
https://www.sartorius.com/en/company-fr/investor-relations-fr/sartorius-stedim-biotech-sa-investor-relations-fr
The documents posted online include business development for the period January to June 2024 as well as forecasts for the year. The consolidated accounts for the period ended June 30, 2024 are also available.
The company, based in Aubagne, is an international leader in the biopharmaceutical field. Listed on Euronext Paris, Sartorius Stedim Biotech provides solutions for the manufacturing of biotechnological medicines. In 2023, the group achieved a turnover of 2.8 billion euros and currently employs 10,600 people around the world.
R. E.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de SARTORIUS STED BIO